KUALA LUMPUR, April 17 (Bernama) -- Recursion, a clinical stage TechBio company has appointed Dr Najat Khan as Chief R&D Officer and Chief Commercial Officer, to lead its research and development, and build its emerging commercial capabilities.
According to Recursion in a statement, Dr Khan has also been appointed to the company’s Board of Directors.
“Najat brings a unique blend of leadership in biological, chemical, and medical sciences, data science, and business. More importantly, she has a vision and passion for transforming drug discovery and development that complements ours and she has a strong sense of urgency to accelerate the industry’s future.
“We are excited to welcome her as a Recursionaut to drive our portfolio pipeline, as well as create commercial strategies as we continue to industrialise the creation of high impact medicines,” said Recursion Co-Founder and Chief Executive Officer, Chris Gibson.
Meanwhile, Dr Khan said: “My mission and focus has been to harness the power of science, data, and AI to revolutionise the way we discover, develop, and deliver transformative medicines for patients.
“This seamlessly aligns with Recursion’s goal to pioneer the burgeoning TechBio sector and decode biology and chemistry to radically improve lives. I believe their approach represents the future of our industry, and sets Recursion to be at the forefront to deliver on this vision.”
Dr Khan has deep expertise in the pharmaceutical and healthcare industry, spanning biological, chemical, and medical science, computational and data science, and general business leadership, with a focus on driving substantial patient and business value.
She also serves as a board member for Alliance for Artificial Intelligence in Healthcare and is a Steering Committee member of the White House’s Moonshot CancerX programme to enhance outcomes for cancer patients.
-- BERNAMA
No comments:
Post a Comment